

Supplemental Table 1

Studies Included in Systematic Review

Author and Year	Sample Characteristics			Included in Stage 1 Meta-Analysis
	Community or Clinical	Mean Age or Age Range	% Male	
Almeida et al., 2007	Community	70+	100.0%	Y
Almeida et al., 2009	Community	70-85	100.0%	Y
Appleton et al., 2011	Community	42.2	41.5%	N
Arai et al., 2006	Clinical	75.6	40.0%	N
Arts et al., 2015	Clinical	70.8	33.9%	N
Au et al., 2014	Community	65.6	44.6%	N
Au et al., 2015	Community	64.6	50.8%	N
Azar et al., 2012	Community	56.3	48.0%	N
Bahrini et al., 2016	Clinical	39.5	41.1%	N
Bai et al., 2014	Clinical	41.9	31.0%	N
Bai et al., 2015	Clinical	43.5	32.4%	N
Baune et al., 2012	Community	78.8	44.8%	Y
Berk et al., 1997	Clinical	41.9	36.4%	N
Bjerkeset et al., 2011	Clinical	55.6	46.0%	Y
Bremmer et al., 2008	Community	70.0	48.9%	Y
Camacho et al., 2014	Community	62.2	48.0%	N
Carpenter et al., 2012	Community	30.5	48.9%	Y

Case & Stewart, 2014	Community	44.3	50.8%	Y
Chang et al., 2012	Clinical	38.8	31.5%	N
Chang et al., 2014	Community	35.6	0.0%	N
Chocano-Bedoya et al., 2014	Community	58.3	0.0%	N
Christian et al., 2011	Community	63.8	26.0%	N
Cizza et al., 2009	Clinical	35.4	0.0%	N
Clark et al., 2011	Community	63.2	28.3%	N
Copeland et al., 2012	Community	21.0	51.3%	N
Courtet et al., 2015	Clinical	39.8	27.8%	N
Crnković et al., 2012	Clinical	22-55	48.7%	N
Cubała & Landowski, 2014	Clinical	32.0	42.5%	N
Danese et al., 2008	Community	32.0	52.0%	N
Danner et al., 2003	Community	17-39	48.9%	Y
Dawood et al., 2007	Clinical	43.1	48.7%	N
de Menezes et al., 2017	Community	51.0	45.7%	Y
Deverts et al., 2010	Community	40.2	45.0%	N
Dome et al., 2009	Clinical	40.5	12.2%	N
Douglas et al., 2004	Community	44.0	82.0%	Y

Dressler et al., 2006	Community	40.9	38.8%	N
Duivis et al., 2013	Clinical	41.9	33.2%	N
Einvik et al., 2011	Community	48.0	56.0%	Y
Einvik et al., 2013	Community	48.0	54.6%	Y
Elderkin-Thompson et al., 2012	Clinical	69.4	28.7%	N
Elovainio et al., 2006	Community	31.5	40.6%	Y
Elovainio et al., 2009	Community	52.3	45.0%	Y
Elovainio et al., 2012	Community	31.7	44.8%	N
Empana et al., 2005	Community	50-59	100.0%	N
Eurelings et al., 2015	Community	74.2	39.3%	Y
Flöck et al., 2010	Clinical	44.4	44.0%	N
Ford & Erlinger, 2004	Community	28.4	45.6%	N
Forti et al., 2010	Community	74.5	45.0%	Y
Frodl et al., 2012	Clinical	39.1	41.0%	Y
Gallagher et al., 2016	Community	66.6	44.9%	N
Gambi et al., 2005	Clinical	41.3	45.9%	Y
Gimeno et al., 2009	Community	50.0	70.0%	N
Glaus et al., 2014	Community	50.9	47.0%	Y

Häfner et al., 2008	Clinical	45.4	42.8%	N
Häfner et al., 2011	Community	50.4	54.8%	Y
Häfner et al., 2012	Community	50.6	51.6%	N
Halder et al., 2010	Community	44.8	50.2%	Y
Hallberg et al., 2010	Clinical	34.1	50.0%	N
Hamer & Chida, 2009	Community	66.5	46.0%	N
Hamer et al., 2009a	Community	63.4	47.4%	N
Hamer et al., 2009b	Community	60.5	46.5%	N
Hamer et al., 2011	Community	62.9	45.2%	N
Hamer et al., 2013	Community	64.5	45.1%	N
Hemingway et al., 2003	Community	55.8	59.4%	N
Henningsson et al., 2008	Community	42.0	0.0%	N
Hickman et al., 2014	Community	29.1	30.1%	Y
Hiles et al., 2015	Community	65.6	49.6%	N
Hornig et al., 1998	Clinical	47.0	45.0%	N
Huang & Lin, 2007	Clinical	33.5	47.8%	N
Hughes et al., 2012	Clinical	39.5	42.3%	Y
Hung et al., 2007	Clinical	23.1	100.0%	N
Jokela et al., 2016	Community	47.5	49.9%	N

Joyce et al., 1992	Clinical	33.4	100.0%	N
Kamiya et al., 2010	Community	65.4	46.3%	N
Karlović et al., 2012	Clinical	48.4	15.5%	N
Kéri et al., 2014	Clinical	23.2	35.0%	Y
Kim et al., 2015	Community	44.4	43.5%	N
Kling et al., 2007	Clinical	38.5	0.0%	N
Kobrosly & van Wijngaarden, 2010	Clinical	20+	48.2%	N
Kodydková et al., 2009	Clinical	64.8	0.0%	N
Komulainen et al., 2007	Community	63.7	0.0%	N
Kop et al., 2002	Community	72.4	39.0%	N
Kop et al., 2010	Community	73.1	40.9%	N
Krogh et al., 2014	Clinical	41.2	38.5%	N
Ladwig et al., 2003	Clinical	57.5	100.0%	N
Ladwig et al., 2005	Community	57.2	100.0%	N
Lai et al., 2016	Community	66.3	47.7%	N
Lamers et al., 2013	Clinical	40.8	35.7%	Y
Lanquillon et al., 2000	Clinical	53.0	38.5%	N
Lasić et al., 2015	Clinical	Unknown	Unknown	N
Legros et al., 1985	Clinical	42.0	Unknown	N

Lehto et al., 2010	Clinical	53.8	31.1%	Y
Lindqvist et al., 2017	Clinical	38.6	42.9%	N
Liu et al., 2014	Community	46.7	49.2%	Y
Liukkonen et al., 2006	Community	31.0	50.6%	N
Liukkonen et al., 2010	Community	32-56	0.0%	N
Loucks et al., 2006	Community	74.3	47.2%	N
Luukinen et al., 2010	Community	78.4	38.6%	N
Ma et al., 2011	Community	48.5	51.0%	N
Maas et al., 2009	Community	85.0	36.0%	N
Matsushima et al., 2015	Community	75.1	26.6%	N
Matthews et al., 2010	Community	46.2	0.0%	N
McDade et al., 2006	Community	59.5	44.7%	N
McDade et al., 2011	Community	67.8	51.3%	N
McDade et al., 2013	Community	35.7	0.0%	N
Meier et al., 2016	Clinical	32.8	32.0%	Y
Melamed et al., 2004	Community	47.2	62.6%	N
Milaneschi et al., 2009	Community	75.0	44.1%	Y
Miller et al., 2002	Clinical	30.0	32.0%	Y
Miller et al., 2003	Clinical	30.3	32.0%	Y
Morris et al., 2011	Community	50.6	38.9%	Y

Mwendwa et al., 2013	Community	45.6	48.0%	Y
Nadkarni & Fristad, 2012	Community	41.0	38.0%	N
Naghashpour et al., 2011	Community	37.0	0.0%	Y
Niu et al., 2008	Community	75.9	43.0%	N
O'Brien et al., 2006*	Clinical	41.6	40.4%	N
O'Donovan et al., 2013	Clinical	49.2	29.0%	N
O'Neil et al., 2014	Clinical	47.5	48.9%	N
Pan et al., 2008	Community	58.6	44.3%	Y
Panagiotakos et al., 2004	Community	44.5	53.1%	Y
Park et al., 2014	Community	65.2	30.0%	N
Pasco et al., 2010	Community	49.0	0.0%	N
Penninx et al., 2003	Community	73.6	48.5%	Y
Pikhart et al., 2009	Community	58.1	46.2%	N
Piletz et al., 2009	Clinical	39.5	15.4%	Y
Pizzi et al., 2008	Community	57.6	51.7%	Y
Pizzi et al., 2010	Community	57.6	51.4%	Y
Poantă et al., 2010	Community	39.5	35.7%	N
Politi et al., 2008	Clinical	53.4	47.0%	Y
Prather et al., 2015	Clinical	42.4	32.7%	N
Priya et al., 2016	Clinical	28.2	52.4%	N

Prohan et al., 2014	Community	21.0	100.0%	Y
Quak et al., 2014	Community	41.9	33.4%	N
Ranjit et al., 2007	Community	62.2	38.5%	Y
Rothermundt et al., 2001	Clinical	44.5	Unknown	N
Rudolf et al., 2014	Clinical	33.1	50.0%	N
Sarandol et al., 2006	Clinical	39.5	27.9%	Y
Savitz et al., 2015a	Clinical	35.8	30.6%	N
Savitz et al., 2015b	Clinical	33.5	35.0%	Y
Schmidt et al., 2015	Clinical	37.0	43.3%	N
Seidel et al., 1995	Clinical	38.9	30.7%	N
Shelton et al., 2015	Clinical	43.2	30.3%	N
Shirom et al., 2010	Community	44.9	72.6%	N
Simanek et al., 2014	Community	54.0	42.0%	N
Slopen et al., 2010	Community	57.9	44.6%	Y
Sluzewska et al., 1995	Clinical	43.5	22.5%	N
Sluzewska et al., 1996a	Clinical	42.3	18.4%	N
Sluzewska et al., 1996b	Clinical	43.4	24.2%	N
Sluzewska et al., 1997	Clinical	44.0	25.0%	N
Smagula et al., 2014	Community	76.4	100.0%	Y

Song et al., 2015	Community	72.1	39.4%	Y
Stephan et al., 2015	Community	69.1	40.0%	N
Steptoe et al., 2003	Community	52.4	54.7%	N
Stewart et al., 2008	Community	60.6	50.9%	Y
Stewart et al., 2009	Community	61.0	48.3%	N
Su et al., 2009	Community	55.0	100.0%	Y
Su et al., 2011	Community	23.1	100.0%	N
Suarez, 2004	Community	27.6	55.1%	Y
Surtees et al., 2008	Community	67.0	63.0%	Y
Taylor et al., 2006	Clinical	62.4	41.2%	N
Teunissen et al., 2016	Clinical	70.4	35.0%	N
Thomas et al., 2005	Clinical	75.4	41.7%	N
Thomas et al., 2007	Clinical	75.5	39.7%	N
Thurston et al., 2011	Community	45.8	0.0%	N
Tiemeier et al., 2003a	Community	73.2	27.0%	N
Tiemeier et al., 2003b	Clinical	72.9	36.1%	N
Toker et al., 2005	Community	45.2	59.7%	Y
Tuglu et al., 2003	Clinical	38.5	60.5%	N
Tully et al., 2015	Community	53.9	100.0%	N
Tully et al., 2016	Community	52.8	100.0%	Y

Uddin et al., 2011	Clinical	45.3	40.0%	N
Uher et al., 2014	Clinical	40.7	37.3%	N
Vaccarino et al., 2008	Community	54.3	100.0%	N
van den Biggelaar et al., 2007	Community	85.0	61.0%	N
Vargas et al., 2013	Clinical	18-60	34.0%	N
Ventorp et al., 2015	Clinical	36.8	45.6%	Y
Verduijn et al., 2015	Clinical	41.8	64.3%	Y
Vetta et al., 2001	Community	80.1	51.1%	N
Vogelzangs et al., 2012	Clinical	41.8	33.0%	Y
Vogelzangs et al., 2014a	Clinical	42.8	36.2%	N
Vogelzangs et al., 2014b	Clinical	70.4	35.2%	N
von Känel et al., 2014	Community	74.3	30.6%	N
White et al., 2017	Community	66.0	45.1%	N
Wium-Andersen et al., 2013	Community	50.7	44.5%	N
Wium-Andersen et al., 2014	Community	57.0	44.5%	N
Wysokiński et al., 2015	Clinical	50.3	38.0%	N
Wysokiński et al., 2016	Clinical	76.7	13.4%	N
Yang et al., 2007	Clinical	50.6	37.8%	N

Zalli et al., 2016	Community	73.0	40.1%	N
Zeman et al., 2009	Clinical	58.5	0.0%	Y
Zoga et al., 2014	Clinical	51.7	0.0%	Y

*O'Brien et al., 2006 presented results from two separate studies within one manuscript and was coded as two separate studies for the systematic review.

References

Almeida O.P., Norman P., Hankey G.J., Jamrozik K. and Flicker L., The association between C-reactive protein concentration and depression in later life is due to poor physical health: results from the Health in Men Study (HIMS), *Psychol. Med.* **37**, 2007, 1775–1786.

- Almeida O.P., Norman P.E., Allcock R., Bockxmeer F.V., Hankey G.J., Jamrozik K. and Flicker L., Polymorphisms of the CRP gene inhibit inflammatory response and increase susceptibility to depression: the Health in Men Study, *Int. J. Epidemiol.* **38**, 2009, 1049–1059.
- Appleton, A.A., Buka, S.L., McCormick, M.C., Koenen, K.C., Loucks, E.B., Gilman, S.E., and Kubzansky, L.D., Emotional functioning at age 7 years is associated with C-reactive protein in middle adulthood, *Psychosom. Med.* **73**, 2011, 295-303.
- Arai, H., Takechi, H., Wada, T., Ishine, M., Wakatsuki, Y., Horiuchi, H., Murayama, T., Yokode, M., Tanaka, M., Kita, T., and Matsubayashi, K., Usefulness of measuring serum markers in addition to comprehensive geriatric assessment for cognitive impairment and depressive mood in the elderly, *Geriatrics & Gerontology International* **6**, 2006, 7-14.
- Arts, M.H., Collard, R.M., Comijs, H.C., Naudé, P.J., Risselada, R., Naarding, P., and Oude Voshaar, R.C., Relationship between physical frailty and low-grade inflammation in late-life depression, *J. Am. Geriatr. Soc.* **63**, 2015, 1652-1657.
- Au, B., Smith, K.J., Gariépy, G., and Schmitz, N., C-reactive protein, depressive symptoms, and risk of diabetes: results from the English Longitudinal Study of Ageing (ELSA), *J. Psychosom. Res.* **77**, 2014, 180-186.
- Au, B., Smith, K.J., Gariépy, G., and Schmitz, N., Longitudinal associations between C-reactive protein and depressive symptoms: evidence from the English Longitudinal Study of Ageing (ELSA), *Int. J. Geriatr. Psychiatry* **30**, 2015, 976-984.
- Azar, R., Nolan, R.P., and Stewart, D.E., Listening to the heart-brain talk: persistent depressive symptoms are associated with hsCRP in apparently healthy individuals at high risk for coronary artery disease, *Eur. J. Prev. Cardiol.* **19**, 2012, 857-863.
- Bahrini, L., Ouanes, S., and Ghachem, R., Inflammatory profile in depression and associated clinical and sociodemographic features in a Middle-Eastern North-African population, *J. Affect. Disord.* **198**, 2016, 122-126.
- Bai, Y.M., Chiou, W.F., Su, T.P., Li, C.T., and Chen, M.H., Pro-inflammatory cytokine associated with somatic and pain symptoms in depression, *J. Affect. Disord.* **155**, 2014, 28-34.
- Bai Y.M., Su T.P., Li C.T., Tsai S.J., Chen M.H., Tu P.C. and Chiou W.F., Comparison of pro-inflammatory cytokines among patients with bipolar disorder and unipolar disorder and normal controls, *Bipolar Disord.* **17**, 2015, 269–277.
- Baune, B.T., Smith, E., Reppermund, S., Air, T., Samaras, K., Lux, O., Brodaty, H., Sachdev, P., & Trollor, J.N. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. *Psychoneuroendocrinology* **37**, 2012, 1521-30.
- Berk, M., Wade, A.A., Kuschke, R.H., and O'Neill-Kerr, A., Acute phase proteins in major depression, *J. Psychosom. Res.* **43**, 1997, 529-534.
- Bjerkeset, O., Romild, U., Smith, G.D., and Hveem, K., The associations of high levels of C-reactive protein with depression and myocardial infarction in 9258 women and men from the HUNT population study, *Psychol. Med.* **41**, 2011, 345-52.

- Bremmer, M.A., Beekman, A.T., Deeg, D.J., Penninx, B.W., Dik, M.G., Hack, C.E., and Hoogendijk, W.J., Inflammatory markers in late-life depression: results from a population-based study, *J. Affect. Disord.* **106**, 2008, 249-55.
- Camacho, A., Larsen, B., McClelland, R.L., Morgan, C., Criqui, M.H., Cushman, M., and Allison, M.A., Association of subsyndromal and depressive symptoms with inflammatory markers among different ethnic groups: the multi-ethnic study of atherosclerosis (MESA), *J. Affect. Disord.* **164**, 2014, 165-170.
- Carpenter, L.L., Gawuga, C.E., Tyrka, A.R., and Price, L.H., C-reactive protein, early life stress, and wellbeing in healthy adults, *Acta. Psychiatr. Scand.* **126**, 2012, 402-10.
- Case, S.M. and Stewart, J.C., Race/ethnicity moderates the relationship between depressive symptom severity and C-reactive protein: 2005-2010 NHANES data, *Brain Behav. Immun.* **41**, 2014, 101-108.
- Chang, H.H., Lee, I.H., Gean, P.W., Lee, S.Y., Chi, M.H., Yang, Y.K., Lu, R.B., and Chen, P.S., Treatment response and cognitive impairment in major depression: association with C-reactive protein, *Brain Behav. Immun.* **26**, 2012, 90-95.
- Chang, M.Y., Tseng, C.H., and Chiou, Y.L., The plasma concentration of copper and prevalence of depression were positively correlated in shift nurses, *Biol. Res. Nurs.* **16**, 2014, 175-181.
- Chocano-Bedoya, P.O., Mirzaei, F., O'Reilly, E.J., Lucas, M., Okereke, O.I., Hu, F.B., Rimm, E.B., and Ascherio, A., C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression, *J. Affect. Disord.* **163**, 2014, 25-32.
- Christian, L.M., Glaser, R., Porter, K., Malarkey, W.B., Beversdorf, D., and Kiecolt-Glaser, J.K., Poorer self-rated health is associated with elevated inflammatory markers among older adults. *Psychoneuroendocrinology* **36**, 2011, 1495-1504.
- Cizza, G., Eskandari, F., Coyle, M., Krishnamurthy, P., Wright, E.C., Mistry, S., Csako, G., and P.O.W.E.R. (Premenopausal, Osteoporosis Women, Alendronate, Depression) Study Group. Plasma CRP levels in premenopausal women with major depression: a 12-month controlled study, *Horm. Metab. Res.* **41**, 2009, 641-648.
- Clark, M.C., Nicholas, J.M., Wassira, L.N., and Gutierrez, A.P., Psychosocial and biological indicators of depression in the caregiving population, *Biol. Res. Nurs.* **15**, 2013, 112-121.
- Copeland W.E., Shanahan L., Worthman C., Angold A. and Costello E.J., Cumulative depression episodes predict later C-reactive protein levels: a prospective analysis, *Biol. Psychiatry* **71**, 2012, 15-21.
- Courtet, P., Jaussent, I., Genty, C., Dupuy, A.M., Guillame, S., Ducasse, D., and Olie, E., Increased CRP levels may be a trait marker of suicidal attempt, *Eur. Neuropsychopharmacol.* **25**, 2015, 1824-1834.
- Crnković, D., Buljan, D., Karlović, D., and Krmek, M., Connection between inflammatory markers, antidepressants and depression, *Acta. Clin. Croat.* **51**, 2012, 25-33.

- Cubala, W.J. and Landowski, J., C-reactive protein and cortisol in drug-naive patients with short-illness-duration first episode major depressive disorder: possible role of cortisol immunomodulatory action at early stage of the disease, *J. Affect. Disord.* **152-154**, 2014, 534-537.
- Danese, A., Moffitt, T.E., Pariante, C.M., Ambler, A., Poulton, R., and Caspi, A., Elevated inflammation levels in depressed adults with a history of childhood maltreatment, *Arch. Gen. Psychiatry* **65**, 2008, 409-415.
- Danner M., Kasl S.V., Abramson J.L. and Vaccarino V., Association between depression and elevated C-reactive protein, *Psychosom. Med.* **65**, 2003, 347-356.
- Dawood T., Lambert E.A., Barton D.A., Laude D., Elghozi J.-L., Esler M.D., Haikerwal D., Kaye D.M., Hotchkin E.J. and Lambert G.W., Specific serotonin reuptake inhibition in major depressive disorder adversely affects novel markers of cardiac risk, *Hypertens. Res.* **30**, 2007, 285-293.
- de Menezes S.T., de Figueiredo R.C., Goulart A.C., Nunes M.A., Benseñor I.M., Viana M.C. and Barreto S.M., Lack of association between depression and C-reactive protein level in the baseline of Longitudinal Study of Adult Health (ELSA-Brasil), *J. Affect. Disord.* **208**, 2017, 448-454.
- Deverts, D.J., Cohen, S., DiLillo, V.G., Lewis, C.E., Kiefe, C., Whooley, M., and Matthews, K.A., Depressive symptoms, race, and circulating C-reactive protein: the Coronary Artery Risk Development in Young Adults (CARDIA) study, *Psychosom. Med.* **72**, 2010, 734-741.
- Dome, P., Teleki, Z., Rihmer, Z., Peter, L., Dobos, J., Kenessey, I., Tovari, J., Timar, J., Paku, S., Kovacs, G., and Dome, B., Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul, *Mol. Psychiatry* **14**, 2009, 523-531.
- Douglas, K.M., Taylor, A.J., and O'Malley, P.G., Relationship between depression and C-reactive protein in a screening population, *Psychosom. Med.* **66**, 2004, 679-683.
- Dressler, W.W., Balieiro, M.C., Ribeiro, R.P., and Dos-Santos, J.E., Depressive symptoms and C-reactive protein in a Brazilian urban community, *Braz. J. Med. Biol. Res.* **39**, 2006, 1013-1019.
- Duivis H.E., Vogelzangs N., Kupper N., de Jonge P. and Penninx B.W., Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from the Netherlands Study of Depression and Anxiety (NESDA), *Psychoneuroendocrinology* **38**, 2013, 1573-1585.
- Einvik, G., Hrubos-Strøm, H., Randby, A., Nordhus, I.H., Somers, V.K., Omland, T., and Dammen, T., Major depressive disorder, anxiety disorders, and cardiac biomarkers in subjects at high risk of obstructive sleep apnea, *Psychosom. Med.* **73**, 2011, 378-384.
- Einvik, G., Flyvbjerg, A., Hrubos-Strøm, H., Randby, A., Frystyk, J., Bjerre, M., Namtvedt, S.K., Kristiansen, H.A., Nordhus, I.H., Somers, V.K., Dammen, T., and Omland, T., Novel cardiovascular risk markers in depression: no association between depressive symptoms and osteoprotegerin adiponectin in persons at high risk for sleep apnea, *J. Affect. Disord.* **145**, 2013, 400-404.
- Elderkin-Thompson, V., Irwin, M.R., Helleman, G., and Kumar, A., Interleukin-6 and memory

functions of encoding and recall in healthy and depressed elderly adults, *Am. J. Geriatr. Psychiatry* **20**, 2012, 753-763.

- Elovainio, M., Keltijangas-Jarvinen, L., Pulkki- Råback, L., Kivimäki, M., Puttonen, S., Viikari, L., Rasanen, L., Mansikkaniemi, K., Viikari, J., and Raitakari, O.T., Depressive symptoms and C-reactive protein: the Cardiovascular Risk in Young Finns Study, *Psychol. Med.* **36**, 2006, 797-805.
- Elovainio, M., Hurme, M., Jokela, M., Pulkki- Råback, L., Kivimäki, M., Hintsanen, M., Hintsala, T., Lehtimäki, T., Vilkkari, J., Raitakari, O.T., and Keltikangas-Järvinen, L., Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study, *Psychosom. Med.* **74**, 2012, 675-681.
- Elovainio M., Aalto A.-M., Kivimäki M., Pirkola S., Sundvall J., Lönnqvist J. and Reunanen A., Depression and C-reactive protein: population-based Health 2000 Study, *Psychosom. Med.* **71**, 2009, 423–430.
- Empana, J.P., Sykes, D.H., Luc, G., Juhan-Vague, I., Arveiler, D., Ferrieres, J., Amouyel, P., Bingham, A., Montaye, M., Ruidavets, J.B., Haas, B., Evans, A., Jouven, X., Ducimetiere, P., and PRIME Study Group, Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME), *Circulation* **111**, 2005, 2299-2305.
- Eurelings L.S., Richard E., Eikelenboom P., van Gool W.A. and van Charante E.P.M., Low-grade inflammation differentiates between symptoms of apathy and depression in community-dwelling older individuals, *Int. Psychogeriatr.* **27**, 2015, 639–647.
- Flöck, A., Zobel, A., Bauriedel, G., Tuleta, I., Hammerstingl, C., Höfels, S., Schuhmacher, A., Maier, W., Nickenig, G., and Skowasch, D., Antiplatelet effects of antidepressant treatment: a randomized comparison between escitalopram and nortriptyline, *Throm. Res.* **126**, 2010, e83-87.
- Ford D.E. and Erlinger T.P., Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey, *Arch. Intern. Med.* **164**, 2004, 1010–1014.
- Forti P., Rietti E., Pisacane N., Olivelli V., Mariani E., Chiappelli M., Licastro F. and Ravaglia G., Blood inflammatory proteins and risk of incident depression in the elderly, *Dement. Geriatr. Cogn. Disord.* **29**, 2010, 11–20.
- Frodl, T., Carballedo, A., Hughes, M.M., Saleh, K., Fagan, A., Skokauskas, N., McLoughlin, D.M., Meaney, J., O'Keane, V., and Connor, T.J., Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder, *Transl. Psychiatry* **13**, 2012, e88.
- Gallagher, D., Kiss, A., Lanctot, K., and Herrmann, N., Depressive symptoms and cognitive decline: A longitudinal analysis of potentially modifiable risk factors in community dwelling older adults, *J. Affect. Disord.* **190**, 2016, 235-240.
- Gambi, F., De Barardis, D., Campanella, D., Carano, A., Sepede, G., Salini, G., Scorrano, B., Spinella, S., Conti, C.M., La Rovere, R., and Valchera, A., A retrospective evaluation of the inflammatory marker C-reactive protein (CRP), cholesterol and high-density lipoproteins in patients with major depression: preliminary findings., *European Journal of Inflammation* **3**, 2005, 127-134.

- Gimeno D., Kivimäki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A., Kumari M., Lowe G.D., Rumley A. and Marmot M.G., Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study, *Psychol. Med.* **39**, 2009, 413–423.
- Glaus, J., Vandeleur, C.L., von Kanel, R., Lasserre, A.M., Strippoli, M.P.F., Gholam-Rezaee, M., Castela, E., Marques-Vidal, P., Bovet, P., Merikangas, K., and Mooser, V. Associations between mood anxiety, or substance use disorders and inflammatory markers after adjustment for multiple covariates in a population-based study. *J. Psychiatr. Res.* **58**, 2014, 36-45.
- Häfner, S., Baghai, T.C., Eser, C., Schule, C., Rupprecht, R., Bondy, B., Bedarida, G., and von Schack, C., C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients, *J. Psychiatr. Res.* **42**, 2008, 163-165.
- Häfner, S., Baumert, J., Emeny, R.T., Lacruz, M.E., Thorand, B., Herder, C., Koenig, W., Rupprecht, R., and Ladwig, K.H., Sleep disturbances and depressed mood: a harmful combination associated with increased leptin levels in women with normal weight, *Biol. Psychol.* **89**, 2012, 163-169.
- Häfner S., Emeny R., Lacruz M., Baumert J., Herder C., Koenig W., Thorand B., Ladwig K. and Investigators K.S., Association between social isolation and inflammatory markers in depressed and non-depressed individuals: results from the MONICA/KORA study, *Brain Behav. Immun.* **25**, 2011, 1701–1707.
- Halder I., Marsland A.L., Cheong J., Muldoon M.F., Ferrell R.E. and Manuck S.B., Polymorphisms in the CRP gene moderate an association between depressive symptoms and circulating levels of C-reactive protein, *Brain Behav. Immun.* **24**, 2010, 160–167.
- Hallberg, L., Janelidze, S., Engstrom, G., Wilsen, A.G., Westrin, A., and Brundin, L., Exercise-induced release of cytokines in patients with major depressive disorder, *J. Affect. Disord.* **126**, 2010, 262-267.
- Hamer M. and Chida, Y., Associations of very high C-reactive protein concentration with psychosocial and cardiovascular risk factors in an ageing population, *Atherosclerosis* **206**, 2009, 599-603.
- Hamer, M., Molloy, G.J., de Oliveira, C., and Demakakos, P., Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: the English Longitudinal Study of Ageing, *Psychoneuroendocrinology* **34**, 2009a, 1050-1055.
- Hamer M., Molloy G.J., de Oliveira C. and Demakakos P., Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship?, *Brain Behav. Immun.* **23**, 2009b, 413–418.
- Hamer M., Poole L., and Messerli-Burgy, N., Television viewing, C-reactive protein, and depressive symptoms in older adults, *Brain Behav. Immun.* **33**, 2013, 29-32.
- Hemingway H., Shipley M., Mullen M.J., Kumari M., Brunner E., Taylor M, Donald A.E., Deanfield J.E., and Marmot, M., Social and psychosocial influences on inflammatory markers and vascular function in civil servants (the Whitehall II study), *Am. J. Cardiol.* **92**, 2003, 984-987.

- Henningsson S, Baghaei F, Rosmond R., Holm G., Landen M., Anckarsater H., and Elkman A., Association between serum levels of C-reactive protein and personality traits in women, *Behav. Brain. Funct.* **4**, 2008, 16.
- Hickman, R.J., Khambaty, T., and Stewart, J.C., C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination survey (NHANES) 1999-2004, *J. Behav. Med.* **37**, 2014, 621-9.
- Hiles SA., Baker AL., de Malmanche T., McEvoy M., Boyle M., and Attia J., Unhealthy lifestyle may increase later depression via inflammation in older women but not men, *J. Psychiatr. Res.* **63**, 2015, 65-74.
- Hornig M., Goodman D.B., Kamoun M., and Amsterdam J.D., Positive and negative acute phase proteins in affective subtypes, *J. Affect. Disord.* **49**, 1998, 9-18.
- Huang T.L., and Lin F.C., High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania, *Prog. Neuropsychopharmacol. Biol. Psychiatry* **31**, 2007, 370-372.
- Hughes, M.M., Carballedo, A., McLoughlin, D.M., Amico, F., Harkin, A., Frodl, T., and Connor, T.J., Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation, *Brain Behav. Immun.* **26**, 2012, 979-87.
- Hung Y.J., Hsieh C.H., Chen Y.J., Pei D., Kuo S.W., Shen D.C., Sheu W.H., and Chen Y.C., Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder, *Clin. Endocrinol (Oxf)*. **67**, 2007, 784-789.
- Jokela M., Virtanen M., Batty G.D. and Kivimäki M., Inflammation and specific symptoms of depression, *JAMA Psychiatry* **73**, 2016, 87–88.
- Joyce P.R., Hawes C.R., Mulder R.T., Sellman J.D., Wilson D.A., and Boswell D.R., Elevated levels of acute phase plasma proteins in major depression, *Biol. Psychiatry* **32**, 1992, 1035-1041.
- Kamiya Y., Whelan B., Timonen V., and Kenny R.A., The differential impact of subjective and objective aspects of social engagement on cardiovascular risk factors, *BMC Geriatr.* **10**, 2010, 81.
- Karlović D., Serretti A., Vrkić N., Martinac M., and Marčinko D., Serum concentrations of CRP, IL-6, TNF- α and cortisol in major depressive disorder with melancholic or atypical features, *Psychiatry Res.* **198**, 2012, 74-80.
- Kéri S., Szabo, C., and Kelemen, O., Expression of Toll-like Receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder, *Brain Behav. Immun.* **40**, 2014, 235-43.
- Kim W.K., Shin D., and Song W.O., Depression and its comorbid conditions more serious in women than in men in the United States, *J. Womens Health (Larchmt)*. **24**, 2015, 978-985.
- Kling M.A., Alesci S., Csako G., Costello R., Luckenbaugh D.A., Bonne O., Duncko R., Drevets

- W.C., Manji H.K. and Charney D.S., Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A, *Biol. Psychiatry* **62**, 2007, 309–313.
- Kobrosly R. and van Wijngaarden E., Associations between immunologic, inflammatory, and oxidative stress markers with severity of depressive symptoms: an analysis of the 2005-2008 National Health and Nutrition Examination Survey, *Neurotoxicology* **31**, 2010, 126-133.
- Kodydková J., Vávrová L., Zeman M., Jiráček R., Macáček J., Staňková B., Tvrzická E., and Žák A., Antioxidative enzymes and increased oxidative stress in depressive women, *Clin. Biochem.* **42**, 2009, 1368-1374.
- Komulainen P., Lakka T.A., Kivipelto M., Hassinen M., Penttilä I.M., Helkala E.L., Gylling H., Nissinen A., and Rauramaa R., Serum high sensitivity C-reactive protein and cognitive function in elderly women, *Age Ageing* **36**, 2007, 443-448.
- Kop W.J., Gottdiener J.S., Tangen C.M., Fried L.P., McBurnie M.A., Walston J., Newman A., Hirsch C., and Tracy R.P., Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia, *Am. J. Cardiol.* **89**, 2002, 419-424.
- Kop W.J., Stein P.K., Tracy R.P., Barzilay J.I., Schulz R., and Gottdiener J.S., Autonomic nervous system dysfunction and inflammation contribute to the increased cardiovascular mortality risk associated with depression, *Psychosom. Med.* **72**, 2010, 626-635.
- Krogh J., Benros M.E., Jørgensen M.B., Vesterager L., Elfving B., and Nordentoft M., The association between depressive symptoms, cognitive function, and inflammation in major depression, *Brain Behav. Immun.* **35**, 2014, 70-76.
- Ladwig K.H., Marten-Mittag B., Lowel H., Doring A., and Koenig W., Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men, *Brain Behav. Immun.* **17**, 2003, 268-275.
- Ladwig K.H., Marten-Mittag B., Lowel H., Doring A., Koenig W., and MONICA-KORA Augsburg Cohort Study 1984-1998, C-reactive protein, depressed mood, and the prediction of coronary heart disease in initially healthy men: results from the. MONICA-KORA Augsburg Cohort Study 1984-1998, *Eur. Heart J.* **26**, 2005, 2537-2542.
- Lai J.S., Oldmeadow C., Hure A.J., McEvoy M., Hiles S.A., Boyle M., and Attia J., Inflammation mediates the association between fatty acid intake and depression in older men and women, *Nutr. Res.* **36**, 2016, 234-245.
- Lamers, F., Vogelzangs, N., Merikangas, K.R., de Jonge, P., Beekman, A.T., and Penninx, B.W., Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression, *Mol. Psychiatry.* **18**, 2013, 692-9
- Lanquillon S., Krieg J., Bening-Abu-Shach U. and Vedder H., Cytokine production and treatment response in major depressive disorder, *Neuropsychopharmacology* **22**, 2000, 370–379.
- Lasić D., Uglešić B., Vujnović Z., and Krnić S., PAI-1 as a component of the metabolic

- syndrome in depression and schizophrenia-Croatian experience, *Psychiatr. Danub.* **27**, 2015, 71-72.
- Legros S., Mendlewicz J., and Wybran J., Immunoglobins, autoantibodies and other serum protein fractions in psychiatric disorders, *Eur. Arch. Psychiatr. Neurol. Sci.* **235**, 1985, 9-11.
- Lehto, S.M., Niskanen, L., Herzig, K.H., Tolmunen, T., Huotari, A., Vinamaki, H., Koivumaa-Honkanen, H., Honkalampi, K., Ruotsalainen, H., and Hintikka, J., Serum chemokine levels in major depressive disorder, *Psychoneuroendocrinology* **35**, 2010, 226-232.
- Lindqvist D., Dhabhar F.S., James S.J., Hough C.M., Jain F.A., Bersani F.S., Reus V.I., Verhoeven J.E., Epel E.S., Mahan L., Rosser R., Wolkowitz O.M., and Mellon S.H., Oxidative stress, inflammation and treatment response in major depression, *Psychoneuroendocrinology* **76**, 2017, 197-205.
- Liu Y., Al-Sayegh H., Jabrah R., Wang W., Yan F. and Zhang J., Association between C-reactive protein and depression: modulated by gender and mediated by body weight, *Psychiatry Res.* **219**, 2014, 103–108.
- Liukkonen T., Silvennoinen-Kassinen S., Jokelainen J., Rasanen P., Leinonen M., Meyer-Rochow V.B., and Timonen M., The association between C-reactive protein levels and depression: Results from the northern Finland 1966 birth cohort study, *Biol. Psychiatry* **60**, 2006, 825-830.
- Liukkonen T., Vanhala M., Jokelainen J., Keinanen-Kiukaanniemi S., Koponen H., and Timonen M., Effect of menopause and use of contraceptives/hormone therapy on association of C-reactive protein and depression: a population-based study, *J. Psychosom. Res.* **68**, 2010, 573-579.
- Loucks E.B., Berkman L.F., Gruenewald T.L., and Seeman T.E., Relation of social integration to inflammatory marker concentrations in men and women 70 to 79 years, *Am. J. Cardiol.* **97**, 2006, 1010-1016.
- Luukinen H., Jokelainen J., and Hedberg P., The relationship between high-sensitivity C-reactive protein and incident depressed mood among older adults, *Scand. J. Clin. Lab Invest.* **70**, 2010, 75-79.
- Ma Y., Chiriboga D.E., Pagoto S.L., Rosal M.C., Li W., Merriam P.A., Hebert J.R., Whited M.C., and Ockene I.S., Association between depression and C-reactive protein, *Cardiol. Res. Prac.*, 2011.
- Maas D.W., van der Mast R.C., and de Craen A.J., Increased C-reactive protein is not associated with apathy: the Leiden 85-Plus Study, *Int. J. Geriatr. Psychiatry* **24**, 2009, 1177-1184.
- Matsushima J., Kawashima T., Nabeta H., Imamura Y., Watanabe I., Mizoguchi Y., Kojima N., Yamada S., and Monji A., Association of inflammatory biomarkers with depressive symptoms and cognitive decline in a community-dwelling healthy older sample: a 3-year follow-up study, *J. Affect. Disord.* **173**, 2015, 9-14.
- Matthews K.A., Schott L.L., Bromberger J.T., Cyranowski J.M., Everson-Rose S.A., and Sowers, M., Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women?, *Brain Behav. Immun.* **24**, 2010, 96-101.
- McDade T.W., Borja J.B., Adair L.S., and Kuzawa C., Depressive symptoms are not associated

with inflammation in younger and older adults in the Philippines, *Evol. Med. Public Health* **1**, 2013, 18-23.

McDade T.W., Lindau S.T., and Wroblewski K., Predictors of C-reactive protein in the national social life, health, and aging project. *J. Gerontol. B. Psychol. Sci. Soc. Sci.* **66**, 2011, 129-136.

McDade T.W., Hawkey L.C. and Cacioppo J.T., Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging, and social relations study, *Psychosom. Med.* **68**, 2006, 376–381.

Meier, T.B., Drevets, W.C., Wurfel, B.E., Ford, B.N., Morris, H.M., Victor, T.A., Bodurka, J., Teague, T.K., Dantzer, R., and Savitz, J., Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder, *Brain Behav. Immun.* **53**, 2016, 39-48.

Melamed S., Shirom A., Toker S., Berliner S., and Shapira I., Association of fear of terror with low-grade inflammation among apparently healthy employed adults, *Psychosom. Med.* **66**, 2004, 484-491.

Milaneschi, Y., Corsi, A.M., Penninx, B.W., Bandinelli, S., Guralnik, J.M., and Ferrucci, L., Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study, *Biol. Psychiatry* **65**, 2009, 973-978.

Miller, G.E., Freedland, K.E., Carney, R.M., Stetler, C.A. and Banks, W.A., Pathways linking depression, adiposity, and inflammatory markers in healthy young adults, *Brain Behav. Immun.* **17**, 2003, 276-285.

Miller, G.E., Stetler, C.A., Carney, R.M., Freedland, K.E., and Banks, W.A., Clinical depression and inflammatory risk markers for coronary heart disease, *Am. J. Cardiol.* **15**, 2002, 1279-83.

Morris A.A., Zhao L., Ahmed Y., Stoyanova N., De Staercke C., Hooper W.C., Gibbons G., Din-Dzietham R., Quyyumi A., and Vaccarino V., Association between depression and inflammation--differences by race and sex: the META-Health study, *Psychosom. Med.* **73**, 2011, 462-468.

Mwendwa, D.T., Ali, M.K., Sims, R.C., Cole, A.P., Lipscomb, M.W., Levy, S.A., Callender, C.O., and Campbell, A.L., Dispositional depression and hostility are associated with inflammatory markers of cardiovascular disease in African Americans, *Brain Behav. Immun.* **28**, 2013, 72-82.

Nadkarni R.B. and Fristad M.A., Stress and support for parents of youth with bipolar disorder. *Isr. J. Psychiatry Relat. Sci.* **49**, 2012, 104-110.

Naghashpour M., Amani R., Nutr R., Nematpour S. and Haghizadeh M.H., Riboflavin status and its association with serum hs-CRP levels among clinical nurses with depression, *J. Am. Coll. Nutr.* **30**, 2011, 340–347.

Niu K. Hozawa A., Guo H., Kuriyama S., Ebihara S., Yang G., Ohmori-Matsuda K., Nakaya N., Takahashi H., Fujita K., Wen S., Arai H., Tsuji I., and Nagatomi R., Serum C-reactive protein even at very low (<1.0 mg/l) concentration is associated with physical performance in a community-based elderly population aged 70 years and over, *Gerontology* **54**, 2008, 260-267.

- O'Brien S.M., Scott L.V. and Dinan T.G., Antidepressant therapy and C-reactive protein levels, *Br. J. Psychiatry* **188**, 2006, 449–452.
- O'Donovan A., Rush G., Hoatam G., Hughes B.M., McCrohan A., Kelleher C., O'Farrelly C., and Malone K.M., Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder, *Depress. Anxiety* **30**, 2013, 307-314.
- O'Neil A., Berk M., Venugopal K., Kim S.W., Williams L.J., and Jacka F.N., The association between poor dental health and depression: findings from a large-scale, population-based study (the NHANES study), *Gen. Hosp. Psychiatry* **36**, 2014, 266-270.
- Pan A., Ye X., Franco O.H., Li H., Yu Z., Wang J., Qi Q., Gu W., Pang X. and Liu H., The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese, *PLoS One* **3**, 2008, e1392.
- Panagiotakos D.B., Pitsavos C.E., Chrysohoou C.A., Skoumas J., Toutouza M., Belegrios D., Toutouzas P.K. and Stefanadis C., The association between educational status and risk factors related to cardiovascular disease in healthy individuals: the ATTICA study, *Ann. Epidemiol.* **14**, 2004, 188–194.
- Park S., Joo Y.H., McIntyre R.S., and Kim B., Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression, *Psychosomatics* **55**, 2014, 640-649.
- Pasco J.A., Nicholson G.C., Williams L.J., Jacka F.N., Henry M.J., Kotowicz M.A., Schneider H.G., Leonard B.E., and Berk M., Association of high-sensitivity C-reactive protein with de novo major depression, *Br. J. Psychiatry* **197**, 2010, 372-377
- Penninx B.W., Kritchovsky S.B., Yaffe K., Newman A.B., Simonsick E.M., Rubin S., Ferrucci L., Harris T. and Pahor M., Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study, *Biol. Psychiatry* **54**, 2003, 566–572.
- Pikhart H., Hubacek J.A., Kubinova R., Nicholson A., Peasey A., Capkova N., Poledne R., and Bobak M., Depressive symptoms and levels of C-reactive protein: A population-based study, *Soc. Psychiatry Psychiatr. Epidemiol.* **44**, 2009, 217-222.
- Piletz, J.E., Halaris, A., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J., and Devane, C.L., Pro-inflammatory biomarkers in depression: treatment with venlafaxine, *World J. Biol. Psychiatry* **10**, 2009, 313-323.
- Pizzi, C., Manzoli, L., Mancini, S., Bedetti, G., Fontana, F., and Costa, G.M., Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors, *Atherosclerosis* **212**, 2010, 292-298.
- Pizzi, C., Manzoli, L., Mancini, S., and Costa, G.M., Analysis of potential predictors of depression among coronary heart disease risk factors including heart rate variability, markers of inflammation, and endothelial function. *Eur. Heart J.* **29**, 2008, 1110-7.
- Poantă L., Crăciun A., and Dumitrașcu D.L., Professional stress and inflammatory markers in physicians, *Rom. J. Intern. Med.* **48**, 2010, 57-63.
- Politi, P., Brondino, N., and Emanuele, E., Increased proapoptotic serum activity in patients with

chronic mood disorders, *Arch. Med. Res.* **39**, 2008, 242-245.

- Prather A.A., Vogelzangs N., and Penninx B.W.J.H., Sleep duration, insomnia, and markers of systemic inflammation: Results from the Netherlands Study of Depression and Anxiety (NESDA), *J. Psychiatr. Res.* **60**, 2015, 95-102.
- Priya P.K., Rajappa M., Kattimani S., Mohanraj P.S., and Revathy G., Association of neurotrophins, inflammation and stress with suicide risk in young adults, *Clin. Chim. Acta* **457**, 2016, 41-45.
- Prohan M., Amani R., Nematpour S., Jomehzadeh N. and Haghhighizadeh M.H., Total antioxidant capacity of diet and serum, dietary antioxidant vitamins intake, and serum hs-CRP levels in relation to depression scales in university male students, *Redox Rep.* **19**, 2014, 133–139.
- Quak J., Doornbos B., Roest A.M., Duivis H.E., Vogelzangs N., Nolen W.A., Penninx B.W.J.H., Kema I.P and de Jonge P., Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? *Psychoneuroendocrinology* **45**, 2014, 202-210.
- Ranjit N., Diez-Roux A.V., Shea S., Cushman M., Seeman T., Jackson S.A. and Ni H., Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis, *Arch. Intern. Med.* **167**, 2007, 174–181.
- Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A., and Kirchner H., Inflammatory markers in major depression and melancholia, *J. Affect. Disord.* **63**, 2001, 93-102.
- Rudolf S., Greggersen W., Kahl K.G., Huppe M., and Schweiger U., Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression, *Psychiatry Res.* **30**, 2014, 34-38.
- Sarandol, A., Sarandol, E., Eker, S.S., Karaagac, E.U., Hizli, B.Z., Dirican, M., and Kirli, S., Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder, *Prog. Neuropsychopharmacol. Biol. Psychiatry* **30**, 2006, 1103-8.
- Savitz, J., Drevets, W.C., Smith, C.M., Victor, T.A., Wurfel, B.E., Bellgowan, P.S., Bodurka, J., Teague, T.K., and Dantzer, R., Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder, *Neuropsychopharmacology* **40**, 2015a, 463-471.
- Savitz, J., Drevets, W.C., Wurfel, B.E., Ford, B.N., Bellgowan, P.S., Victor, T.A. Bodurka, J., Teague, T.K., and Dantzer, R., Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder, *Brain Behav. Immun.* **46**, 2015b, 55-59.
- Schmidt F.M. Schroder T., Kirkby K.C., Sander C., Suslow T., Holdt, L.M., Teupset D., Hegerl U., and Himmerich H., Pro- and anti-inflammatory cytokines, but not CPR, are inversely correlated with severity and symptoms of major depression, *Psychiatry Res.* **239**, 2016, 85-91.
- Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., and Kirchner H., Cytokine production and serum proteins in depression, *Scand. J. Immunol.* **41**, 1995, 534-538.
- Shelton R.C., Falola M., Li L., Zajecka J., Fava M. and Papakostas G.I., The pro-inflammatory

profile of depressed patients is (partly) related to obesity, *J. Psychiatr. Res.* **70**, 2015, 91–97.

Shirom A., Toker S., and Melamed S., Vigor, anxiety, and depressive symptoms as predictors of changes in fibrinogen and C-reactive protein, *Applied Psychology: Health and Well-Being* **2**, 2010, 251-271.

Simanek A.M., Cheng C., Yolken R., Uddin M., Galea S., and Aiello A.E., Herpesviruses, inflammatory markers and incident depression in a longitudinal study of Detroit residents, *Psychoneuroendocrinology* **50**, 2014, 139-148.

Slopen, N., Lewis, T.T., Gruenewald, T.L., Mujahid, M.S., Ryff, C.D., Albert, M.A., and Williams, D.R., Early life adversity and inflammation in African Americans and whites in the midlife in the United States survey, *Psychosom. Med.* **72**, 2010, 694-701.

Sluzewska A., Rybakowski J.K., Sobieska M., Bosnians E., Pollet H., and Wiktorowicz K., Increased levels of alpha-1-acid glycoprotein and interleukin-6 in refractory depression, *Depression* **3**, 1995, 170-175.

Slusewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., and Wiktorowicz K., Indicators of immune activation in major depression, *Psychiatr. Res.* **64**, 1996a, 161-167.

Sluzewska A., Rybakowski J.K., Sobieska M., and Wiktorowicz K., Concentration and microheterogeneity glycoforms of alpha-1-acid glycoprotein in major depressive disorder. *J. Affect. Disord.* **39**, 1996b, 149-155.

Sluzewska A., Sobieska M., and Rybakowski J.K., Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. *Neuropsychobiology* **35**, 1997, 123-127.

Smagula S.F., Ancoli-Israel S., Barrett-Connor E., Lane N.E., Redline S., Stone K.L., Cauley J.A. and Group O.F.I.M.R., Inflammation, sleep disturbances, and depressed mood among community-dwelling older men, *J. Psychosom. Res.* **76**, 2014, 368.

Song B.M., Lee J.-M., Choi W., Youm Y., Chu S.H., Park Y.-R. and Kim H.C., Association between C reactive protein level and depressive symptoms in an elderly Korean population: Korean Social Life, Health and Aging Project, *BMJ Open* **5**, 2015, e006429.

Stephan Y., Sutin A.R., and Terracciano A., Younger subjective age is associated with lower C-reactive protein among older adults, *Brain Behav. Immun.* **43**, 2015, 33-36.

Stephoe A., Kunz-Ebrecht S. and Owen N., Lack of association between depressive symptoms and markers of immune and vascular inflammation in middle-aged men and women, *Psychol. Med.* **33**, 2003, 667–674.

Stewart J.C., Janicki-Deverts D., Muldoon M.F., and Kamarck T.W., Depressive symptoms moderate the influence of hostility on serum interleukin-6 and C-reactive protein, *Psychosom. Med.* **70**, 2008, 197-204.

Stewart, J.C., Rand, K.L., Muldoon, M.F., and Kamarck, T.W., A prospective evaluation of the directionality of the depression-inflammation relationship, *Brain Behav. Immun.* **23**, 2009, 936-944.

- Su, S., Miller, A.H., Snieder, H., Bremner, J.D., Ritchie, J., Maisano, C., Jones, L., Murrah, N.V., Goldberg, J., and Vaccarino, V., Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study, *Psychosom. Med.* **71**, 2009, 152-8.
- Su S.C., Sun M.T., Wen M.J., Lin C.J., Chen Y.C., and Hung Y.J., Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men, *Intl. J. Psychiatry Medicine* **42**, 2011, 211-226.
- Suarez, E.C., C-reactive protein is associated with psychological risk factors of cardiovascular disease in apparently healthy adult, *Psychosom. Med.* **66**, 2004, 684-691.
- Surtees P.G., Wainwright N.W., Boekholdt S.M., Luben R.N., Wareham N.J. and Khaw K.T., Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women, *Psychosom. Med.* **70**, 2008, 850-855.
- Taylor C.B., Conrad A., Wilhelm F.H., Neri E., De Lorenzo A., Kramer M.A., Giese-Davis J., Roth W.T., Oka R., Cooke J.P., Kraemer H., and Spiegel D., Psychophysiological and cortisol responses to psychological stress in depressed and nondepressed older men and women with elevated cardiovascular disease risk, *Psychosom. Med.* **68**, 2006, 538-546.
- Teunissen C.E., Durieux-Lu S., Blankenstein M.A., Oude Voshaar R.C., and Comijs H.C., The inflammatory marker GDF-15 is not independently associated with late-life depression, *J. Psychiatr. Res.* **83**, 2016, 46-49.
- Thomas A.J., Davis S., Morris C., Jackson E., Harrison R. and O'Brien J.T., Increase in interleukin-1 β in late-life depression, *Am. J. Psychiatry* **162**, 2005, 175-177.
- Thomas A.J., Morris C., Davis S., Jackson E., Harrison R., and O'Brien J.T., Soluble cell adhesion molecules in late-life depression, *Int. Psychogeriatr.* **19**, 2007, 914-920.
- Thurston R.C., El Khoudary S.R., Sutton-Tyrrell K., Crandall C.J., Gold E., Sternfeld B., Selzer F., and Matthesw, K.A., Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? Findings from the Study of Women's health Across the Nation, *Menopause* **18**, 2011, 1044-1051.
- Tiemeier H., Hofman A., Ruud van Tuijl H., Kiliaan A.J., Meijer J., and Breteler M.M.B., Inflammatory proteins and depression in the elderly, *Epidemiology* **14**, 2003a, 103-107.
- Tiemeir H., Ruud van Tuijl H., Hofman A., Kiliaan A.J., and Breteler M.M.B., Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study, *Am, J. Clin. Nutr.* **78**, 2003b, 40-46.
- Toker, S., Shirom, A., Shapira, I., Berliner, S., and Melamed, S., The association between burnout, depression, anxiety, and inflammation biomarkers: C-reactive protein and fibrinogen in men and women, *J. Occup. Health Psychol.* **10**, 2005, 344-362.
- Tuglu C., Kara S.H., Caliyurt O., Vardar E. and Abay E., Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder, *Psychopharmacology* **170**, 2003, 429-433.

- Tully P.J., Baumeister H., Bengel J., Jenkins A., Januszewski A., Martin S., and Wittert G.A., The longitudinal association between inflammation and incident depressive symptoms in men: the effects of hs-CRP are independent of abdominal obesity and metabolic disturbances, *Physiol. Behav.* **139**, 2015, 328-335.
- Tully, P.J., Baumeister, H., Martin, S., Atlantis, E., Jenkins, A., Januszewski, A., O'Loughlin, P., Taylor, A., Wittert, G.A., and Florey Adelaide Male Ageing Study, Elucidating the biological mechanisms linking depressive symptoms with Type 2 diabetes in men: the longitudinal effects of inflammation, microvascular dysfunction, and testosterone, *Psychosom. Med.* **78**, 2016, 221-232.
- Uddin M., Koenen K.C, Aiello A.E., Wildman D.E., de los Santos R., and Galea S., Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample, *Psychol. Med.* **41**, 2011, 997-1007.
- Vaccarino V., Brennan M.L., Miller A.H., Bremner J.D., Ritchie J.C., Lindau F., Veledar E., Su S., Murrah N.V., Jones L., Jawed F., Dai J., Goldberg J., and Hazen S.L., Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: A twin study, *Biol. Psychiatry* **64**, 2008, 476-483.
- van den Biggelaar A.H., Gussekloo J., de Craen A.J., Frolich M., Stek M.L., van der Mast R.C., and Westendorp R.G., Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age, *Exp. Gerontol.* **42**, 2007, 693-701.
- Vargas H.O., Nunes S.O., de Castro M.R., Vargas M.M., Barbosa D.S. Bortolasci C.C., Venugopal K., Dodd S., and Berk M., Oxidative stress and inflammatory markers are associated with depression and nicotine dependence, *Neurosci. Lett.* **544**, 2013, 136-140.
- Ventorp, F., Gustafsson, A., Traskman-Bendz, L., Westrin, A., and Ljunggren, L., Increased soluble urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters, *PLoS One* **10**, 2015, e0140052.
- Verduijn, J., Milaneschi, Y., Schoevers, R.A., van Hemert, A.M., Beekman, A.T., and Penninx, B.W., Pathophysiology of major depressive disorder: mechanisms involved in etiology are not associated with clinical progression, *Transl. Psychiatry* **29**, 2015, e649.
- Vetta F., Ronzoni S., Lupattelli M.R., Novi B., Fabbriconi P., Ficoneri C., Cicconetti P., Bruno A., Russo R., Bollea M.R., Tumor necrosis factor- α and mood disorders in the elderly, *Arch. Gerontol. Geriatr.* **7**, 2001, 435-442.
- Vogelzangs N., Beekman A.T.F., van Reedt Dortland A.K.B., Schoevers R.A., Giltay E.J., de Jonge P., and Penninx B.W.J.H., Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users, *Neuropsychopharmacology* **39**, 2014a, 1624-1634.
- Vogelzangs N., Comijs H.C., Oude Voshaar R.C., Stek M.L., and Penninx B.W.J.H., Late-life depression symptom profiles are differentially associated with immunometabolic functioning, *Brain Behav. Immun.* **41**, 2014b, 109-115.
- Vogelzangs, N., Duijvis, H.E., Beekman, A.T., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J.H., de Jonge, P., and Penninx, B.W., Association of depressive disorders, depression characteristics and antidepressant medication with inflammation, *Transl. Psychiatry* **21**, 2012, e79.

- von Känel R., Mausbach B.T., Mills P.J., Dimsdale J.E., Patterson T.L., Ancoli-Israel S., Ziegler M.G., Allison M., Chattillion E.A., and Grant I., Longitudinal relationship of low leisure satisfaction but not depressive symptoms with systemic low-grade inflammation in dementia caregivers, *J. Gerontol. B. Psychol. Sci. Soc. Sci.* **69**, 2014, 397-407.
- White J., Kivimäki M., Jokela M. and Batty G.D., Association of inflammation with specific symptoms of depression in a general population of older people: the English Longitudinal Study of Ageing, *Brain Behav. Immun.* **61**, 2017, 27–30.
- Wium-Andersen, M.K., Ørsted, D.D., Nielsen, S.F., and Nordestgaard, B.G., Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals, *JAMA Psychiatry* **70**, 2013, 176-184.
- Wium-Andersen M.K., Ørsted D.D., and Nordestgaard B.G., Elevated C-reactive protein, depression, somatic diseases, and all-cause mortality: A Mendelian randomization study, *Biol. Psychiatry* **76**, 2014, 249-257.
- Wysokiński A., Socha K., Sołtysik B.K., Kłoszewska I., Sobów T., and Kostka T., Levels of C-reactive protein (CRP) in elderly patients with unipolar depression--case control analysis, *Nord. J. Psychiatr.* **70**, 2016, 503-507.
- Wysokiński A., Margulska A., Strzelecki D., and Kłoszewska I., Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar depression, *Nord. J. Psychiatr.* **69**, 2015, 346-353.
- Yang E.H., Lerman S., Lennon R.J., Simari R.D., Lerman L.O., and Lerman A., Relation of depression to coronary endothelial function, *Am. J. Cardiol.* **99**, 2007, 1134-1136.
- Zalli A., Jovanova O., Hoogendijk W.J.G., Tiemeier H., and Carvalho L.A., Low-grade inflammation predicts persistence of depressive symptoms, *Psychopharmacology* **233**, 2016, 1669-1678.
- Zeman, M., Jirak, R., Jachymova, M., Vecka, M., Tvrzicka, E., and Zak, A., Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women, *Neuro. Endocrinol. Lett.* **30**, 2009, 387-395.
- Zoga, M., Oulis, P., Chatzipanagiotou, S., Masdrakis, V.G., Pilatsika, P., Boufidou, F., Foteli, S., Soldatos, C.R., Nikolaou, C., and Papageorgiou, C., Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females, *In Vivo* **28**, 2014, 633-638.